SPARC family proteins: matricellular modulators of cancer progression and therapeutic resistance

Cancer Gene Therapy · Published 2026-04-13 · DOI 10.1038/s41417-026-01028-5

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1038/s41417-026-01028-5

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• The role of STAT3 in regulating ferroptosis in cancer: molecular mechanisms and targeted therapeutic perspectives · Cancer Gene Therapy · 2026 · Same journal
• b-AP15 enhances TRAIL-induced cell death in HNSCC via the induction of ROS/JNK/DR5 signalling · Cancer Gene Therapy · 2026 · Same journal
• COL3A1 promotes gastric cancer progression by activating PI3K/AKT signaling · Cancer Gene Therapy · 2026 · Same journal
• Inhibiting CXCL12/CXCR4 axis enhances T cell activity in gastric cancer · Cancer Gene Therapy · 2026 · Same journal
• Memory programming and new manufacturing paradigms in CAR-T cell therapy · Cancer Gene Therapy · 2026 · Same journal
• Dioscin suppresses tumorigenesis and overcomes radioresistance by promoting ubiquitination-mediated degradation of Mcl-1 · Cancer Gene Therapy · 2026 · Same journal
• HOXC11 promotes head and neck squamous cell carcinomas (HNSCC) progression by regulating SPHK1 through the Wnt signaling pathway · Cancer Gene Therapy · 2026 · Same journal
• The Tumor-suppressive role of CNTNAP2 in glioma: Dual regulation of the NDN-ERK axis and M2 macrophage polarization · Cancer Gene Therapy · 2026 · Same journal
• Reprogramming the tumor microenvironment via TFF3 targeting: a potential novel avenue to boost CAR-T cell therapy in solid tumors · Cancer Gene Therapy · 2026 · Same journal
• LMTK3 regulates breast cancer angiogenesis via a context-dependent mesenchymal-epithelial transition program · Cancer Gene Therapy · 2026 · Same journal